Interchangeability: FDA Sets ‘Stringent’ Standard On Design Differences

Sponsors must assess any differences in a biosimilar’s container closure system or delivery device relative to the US reference product and may need to conduct comparative use human factor studies to ensure there is no increased risk of use-related error with the biosimilar.

The US FDA has shown a willingness to license biosimilars with container closure systems or delivery devices that differ from the reference biologic, but interchangeability determinations may be harder to come by for such products.

FDA’s recently released draft guidance on interchangeability considerations discusses how differences in product presentation between a biosimilar and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

FDA Dampens Outlook With Another Ophthalmic Bevacizumab CRL

 
• By 

After pinning its hopes on a trial that did not meet its primary endpoint, Outlook Therapeutics is disappointed that the US FDA has again rejected its Lytenava ophthalmic formulation of bevacizumab, with the firm pointing to “only one deficiency, for a lack of substantial evidence of effectiveness.”

Teva Claims A First With US Launch Of Liraglutide For Weight Loss

 
• By 

Teva has announced the approval and launch of the first generic GLP-1 indicated for weight loss in the US, with the introduction of its liraglutide rival to Saxenda.

Generic Industry Looking For Expanded Inspections As US FDA Rehires Staff

 
• By 

Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.

EU Industry Welcomes Generics Exemption From US Tariffs

 
• By 

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.

More from Policy & Regulation

Aeon Expects Imminent Data On Botox Biosimilar

 
• By 

Aeon Biopharma says it expects to complete primary structure and select functional analyses for its ABP-450 proposed biosimilar to Botox by the end of the current quarter, ahead of a meeting with the FDA in late 2025 to discuss next steps.

Vanda Slams FDA ‘Generic Bias’ As It Again Seeks To Undo Hetlioz ANDA Approvals

 
• By 

In its latest attempt to curtail generic versions of Hetlioz, Vanda Pharmaceuticals has called on US FDA commissioner Marty Makary to reverse a previous agency decision upholding two ANDA approvals, claiming an “unacceptable culture of bias toward approving generic drugs” at the FDA.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By 

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.